Technology
Health
Biotechnology

Affimed

$3.04
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.10 (3.33%) Today
-$0.06 (-2.10%) After Hours

Why Robinhood?

You can buy or sell Affimed and other stocks, options, ETFs, and crypto commission-free!

About

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. Read More The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Employees
69
Headquarters
Heidelberg, Baden Wuerttemberg
Founded
2000
Market Cap
187.29M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.09M
High Today
$3.11
Low Today
$2.99
Open Price
$3.00
Volume
409.45K
52 Week High
$7.35
52 Week Low
$1.40

Collections

Technology
Health
Biotechnology
Cancer Prevention
2014 IPO
Europe (Non-UK)
Europe

News

Yahoo FinanceMay 22

Affimed N.V. Q1 2019 Earnings Call Transcript

Logo of jester cap with thought bubble. Image source: The Motley Fool. Affimed N.V. (NASDAQ: AFMD) Q1 2019 Earnings Call May 22, 2019, 8:30 a.m. ET Scroll to continue with content Ad Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day and welcome to Affimed First Quarter 2019 Financial Results and Corporate Update Conference Call. At this time all participants are in a listen-only mode. As a reminder, today's conference is being recorded. I'll ...

1
Seeking AlphaMay 22

Affimed bails on AFM11; shares down 9% premarket

Affimed N.V. (NASDAQ:AFMD) plans to focus its R&D investments on advancing clinical trials for innate cell engager candidates, AFM13 and AFM24 and also provides corporate updates.

75
Yahoo FinanceApr 30

Affirmed Therapeutics (AFMD) Moves to Buy: Rationale Behind the Upgrade

Affirmed Therapeutics (AFMD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects.

347

Earnings

-$0.22
-$0.09
$0.04
$0.17
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.17 per share
Actual
$0.03 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.